Seven pharmaceutical companies have launched biosimilars of AbbVie's arthritis drug Humira, sparking calls for reform in drug pricing intermediaries. Despite the increased competition, prices remain high, highlighting the need for reform in the pharmaceutical supply chain. The Biden administration has prioritized lowering drug prices and passed the Inflation Reduction Act, targeting pharmacy benefit managers (PBMs). Amgen, which launched its biosimilar to Humira, argues that PBMs favor higher list prices for subsequent after-market discounts. Novartis's Sandoz unit has also launched biosimilars.